Russia and Kazakhstan finalise plan for nuclear plant construction
Russia and Kazakhstan have signed a formal agreement to move forward with the construction of a nuclear power plant in Kazakhstan, marking a key step in their energy cooperation.
French pharmaceutical giant Sanofi announced Monday that it will acquire U.S.-based Blueprint Medicines for $9.1 billion to strengthen its portfolio in rare immunological diseases.
France-based pharmaceutical company Sanofi announced Monday that it will acquire U.S.-based Blueprint Medicines Corporation for $9.1 billion, in a strategic move to bolster its presence in rare immunological diseases.
Blueprint, a biopharmaceutical company specializing in systemic mastocytosis (SM) and other KIT-driven diseases, accepted Sanofi’s offer of $129 per share in cash. The offer represents a 27% premium over Blueprint’s last closing price of $101.35 on Friday.
The acquisition includes Ayvakit (avapritinib), a treatment for SM approved in both the U.S. and EU, along with a robust early- and late-stage immunology pipeline.
“Blueprint’s established relationships with allergists, dermatologists, and immunologists are expected to enhance Sanofi’s growing immunology portfolio,” the French company said in a statement.
The transaction is expected to close in the third quarter of 2025, pending regulatory approvals.
As part of the deal, Blueprint shareholders will also receive one non-tradeable contingent value right (CVR), entitling them to potential milestone payments of $2 and $4 per CVR based on future achievements.
Blueprint is currently the only company with an approved drug for systemic mastocytosis - a rare disorder caused by excess mast cells - and is also developing next-generation therapies for SM and other immune disorders.
The acquisition marks the largest healthcare M&A deal in Europe so far this year. It follows Sanofi’s recent purchase of Vigil Neuroscience for $470 million last month - the second time the French company has acquired Vigil in 2025, after an initial purchase in January.
Iranian missiles struck multiple locations across Israel and neighbouring regions early Friday morning, including a Microsoft office complex, according to emergency responders and local media reports.
Peace is no longer a dream. It is a discussion. On the streets of Baku and Yerevan, it is also a question, of trust, of foreign interests, and of who truly wants it.
Israeli strikes have reportedly targeted areas near the residences of Iran’s Supreme Leader Ayatollah Ali Khamenei and President Masoud Pezeshkian, according to the New York Times, citing local witnesses.
The 2025 G7 Leaders’ Summit was held June 15–17 in Kananaskis, Alberta, under Canada’s presidency. Prime Minister Mark Carney framed the meeting around priorities of protecting communities, energy and climate security, the digital transition, and future partnerships.
Start your day informed with AnewZ Morning Brief: here are the top news stories for June 17th, covering the latest developments you need to know.
China has successfully mastered the technology to produce Yttrium-90, a critical medical isotope used in radiation therapy for liver cancer, within a commercial nuclear reactor.
German biotech firm BioNTech (22UAy.DE), has agreed to acquire domestic peer CureVac, for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.
Revolutionizing Heart Care: How Artificial Intelligence Powered Digital Twins Are Shaping the Future of Medicine
Researchers at the University of Miami have discovered 230 new giant viruses in global ocean waters, shedding light on their hidden role in marine ecosystems and their potential impact on public health.
Mayo Clinic researchers have validated a blood test's high precision for diagnosing patients with cognitive impairment.This non-invasive, cost-effective breakthrough, detailed in Alzheimer's & Dementia, offers much-needed hope for earlier intervention and better management.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment